Literature DB >> 21744478

The long road to immunotherapy for childhood rhabdomyosarcoma.

Elaine Huang1, Brian P Rubin, Charles Keller.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21744478      PMCID： PMC6250431          DOI： 10.1002/pbc.23136

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


× No keyword cloud information.
  13 in total

1.  The fetal form of the acetylcholine receptor distinguishes rhabdomyosarcomas from other childhood tumors.

Authors:  S Gattenloehner; A Vincent; I Leuschner; S Tzartos; H K Müller-Hermelink; T Kirchner; A Marx
Journal:  Am J Pathol       Date:  1998-02       Impact factor: 4.307

2.  Mutation and expression analyses of the MET and CDKN2A genes in rhabdomyosarcoma with emphasis on MET overexpression.

Authors:  Yuyan Chen; Junko Takita; Masashi Mizuguchi; Kiyoshi Tanaka; Kohmei Ida; Katsuyoshi Koh; Takashi Igarashi; Ryoji Hanada; Yukichi Tanaka; Myoung-Ja Park; Yasuhide Hayashi
Journal:  Genes Chromosomes Cancer       Date:  2007-04       Impact factor: 5.006

3.  [Adoptive T-cell therapy of rhabdomyosarcoma].

Authors:  K Simon-Keller; A Paschen; S Eichmüller; S Gattenlöhner; S Barth; E Koscielniak; I Leuschner; P Stöbel; A Hombach; H Abken; A Marx
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

4.  Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma.

Authors:  Brian P Rubin; Koichi Nishijo; Hung-I Harry Chen; Xiaolan Yi; David P Schuetze; Ranadip Pal; Suresh I Prajapati; Jinu Abraham; Benjamin R Arenkiel; Qing-Rong Chen; Sean Davis; Amanda T McCleish; Mario R Capecchi; Joel E Michalek; Lee Ann Zarzabal; Javed Khan; Zhongxin Yu; David M Parham; Frederic G Barr; Paul S Meltzer; Yidong Chen; Charles Keller
Journal:  Cancer Cell       Date:  2011-02-15       Impact factor: 31.743

5.  Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes.

Authors:  Juliet N Barker; Ekaterina Doubrovina; Craig Sauter; Jennifer J Jaroscak; Miguel A Perales; Mikhail Doubrovin; Susan E Prockop; Guenther Koehne; Richard J O'Reilly
Journal:  Blood       Date:  2010-09-08       Impact factor: 22.113

6.  Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study.

Authors:  Ramzi Dagher; Lauren M Long; Elizabeth J Read; Susan F Leitman; Charles S Carter; Maria Tsokos; Theresa J Goletz; Nilo Avila; Jay A Berzofsky; Lee J Helman; Crystal L Mackall
Journal:  Med Pediatr Oncol       Date:  2002-03

7.  Adoptive transfer of T(reg) depleted autologous T cells in advanced renal cell carcinoma.

Authors:  Fiona C Thistlethwaite; Eyad Elkord; Richard W Griffiths; Deborah J Burt; Alaaeldin M Shablak; John D M Campbell; David E Gilham; Eric B Austin; Peter L Stern; Robert E Hawkins
Journal:  Cancer Immunol Immunother       Date:  2007-09-27       Impact factor: 6.968

Review 8.  Adoptive T cell therapy for cancer in the clinic.

Authors:  Carl H June
Journal:  J Clin Invest       Date:  2007-06       Impact factor: 14.808

9.  Immune-based therapies for sarcoma.

Authors:  Seth M Pollack; Elizabeth T Loggers; Eve T Rodler; Cassian Yee; Robin L Jones
Journal:  Sarcoma       Date:  2011-01-23

10.  The transcriptional activator PAX3-FKHR rescues the defects of Pax3 mutant mice but induces a myogenic gain-of-function phenotype with ligand-independent activation of Met signaling in vivo.

Authors:  Frédéric Relaix; Mariarosa Polimeni; Didier Rocancourt; Carola Ponzetto; Beat W Schäfer; Margaret Buckingham
Journal:  Genes Dev       Date:  2003-12-01       Impact factor: 11.361
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.